ALT Logo

Altimmune, Inc. (ALT) 

NASDAQ
Market Cap
$617.36M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
338 of 774
Rank in Industry
197 of 433

Largest Insider Buys in Sector

ALT Stock Price History Chart

ALT Stock Performance

About Altimmune, Inc.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known …

Insider Activity of Altimmune, Inc.

Over the last 12 months, insiders at Altimmune, Inc. have bought $0 and sold $110,547 worth of Altimmune, Inc. stock.

On average, over the past 5 years, insiders at Altimmune, Inc. have bought $5.72M and sold $718,037 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 300 shares for transaction amount of $863 was made by Drutz David (director) on 2023‑08‑15.

List of Insider Buy and Sell Transactions, Altimmune, Inc.

2024-08-19Saledirector
16,011
0.0206%
$6.90$110,547-9.02%
2023-08-15Purchasedirector
300
0.0006%
$2.88$863+149.13%
2023-03-24PurchaseChief Financial Officer
10,000
0.0213%
$4.31$43,140-5.32%
2023-03-23PurchaseChief Medical Officer
10,000
0.0215%
$4.22$42,200-2.39%
2023-03-23Purchasedirector
9,000
0.0195%
$4.27$38,430-2.39%
2022-12-22Saledirector
20,000
0.0383%
$15.01$300,268-73.88%
2022-08-30SalePresident and CEO
20,000
0.0429%
$20.02$400,322-47.31%
2022-08-12SalePresident and CEO
15,000
0.0264%
$15.06$225,890-39.75%
2022-08-12Saledirector
2,714
0.0048%
$15.00$40,710-39.75%
2022-07-01SaleChief Scientific Officer
10,182
0.022%
$12.00$122,184+0.62%
2022-06-29SaleChief Scientific Officer
5,462
0.0117%
$12.00$65,546-3.74%
2022-06-27SaleChief Scientific Officer
37,352
0.0803%
$12.00$448,254-3.40%
2022-06-27Sale
17,610
0.0371%
$11.75$206,944-3.40%
2022-06-15Purchase
1,000
0.002%
$8.00$8,000+36.66%
2022-05-24Purchase
1,200
0.0024%
$4.50$5,400+140.89%
2022-02-28SaleChief Medical Officer
30,000
0.0692%
$7.52$225,600+52.50%
2021-03-01Saledirector
6,000
0.0151%
$16.08$96,480-28.09%
2020-12-10Purchasedirector
2,000
0.0076%
$11.99$23,980+5.50%
2020-12-01Saledirector
1,227
0.0047%
$13.54$16,614-6.30%
2020-11-30Saledirector
2,500
0.0096%
$12.00$30,000+6.26%

Insider Historical Profitability

<0.0001%
Drutz Daviddirector
41958
0.059%
$8.6861+23.34%
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.10 percent owner
6626403
9.3166%
$8.6813<0.0001%
EVNIN LUKE10 percent owner
6347614
8.9246%
$8.6820
MPM BIOVENTURES III LLC10 percent owner
6347614
8.9246%
$8.6820
Venrock Healthcare Capital Partners III, L.P.10 percent owner
4500000
6.3269%
$8.6840+64.5%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
State Street$88.05M12.28.65M+752.53%+$77.72M<0.01
BlackRock$41.15M5.74.04M-0.06%-$25,256.58<0.01
The Vanguard Group$31.85M4.413.13M-12.41%-$4.51M<0.01
Tang Capital Management, LLC$28M3.882.75M0%+$00.11
Morgan Stanley$22.52M3.122.21M+112.5%+$11.92M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.